Capricor Therapeutics, Inc. CAPR 深 沪
已收盘 08-14 16:00:00 美东时间
6.65
+2.440
+57.96%
华盛通- 最 高8.15
- 今 开7.66
- 成交量 6629.24万股
- 最 低 6.04
- 昨 收 4.21
- 总市值 3.85亿
- 52周最高 40.37
- 市盈率 静 --
- 换手率 114.47%
- 52周最低 2.96
- 委 比 -41.91%
- 总股本 5791.19万
- 历史最高 171.50
- 量 比 11.22
- 振 幅 50.12%
- 历史最低 0.88
- 每 手 1
- 风险率 10.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval
Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading higher on Friday after the gene therapy company released second-quarter earnings on Thursday after market close. The company is actively engaged with the FDA regarding the Biologics License Application (BLA) for Deramiocel. A recent Bioresear...
08-14 21:25
Market-Moving News for August 14th
AMAT: -5% | Applied Materials shares are trading lower after the company reported Q3 financial results. Weakness may be related to elevated investor expectations. AKAN: 100% | Akanda shares are trading higher after the company announced its subsidiary, First Towers & Fiber, provided an update on i...
08-14 19:25
Capricor surges on amended plans for lead drug
Shares of Capricor Therapeutics (CAPR) climbed more than 100% in the premarket on Friday after the cell therapy developer announced plans to submit an amended marketing application for its lead drug, ...
08-14 19:18
Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why
Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are trending on Friday. Shares of the clinical-stage biotechnology company climbed 67.22% to $7.04 after the bell on Thursday. In the regular session, CAPR closed at $4.21, up 0.48%, according to Benzinga Pro data. The stock saw elevated trading activi...
08-14 13:19
财报速睇 | Capricor Therapeutics, Inc. 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.41亿美元，同比亏损扩大57.2%
华盛资讯8月14日讯，Capricor Therapeutics, Inc.公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.41亿美元，同比亏损扩大57.2%。
08-14 05:35
Capricor Therapeutics Q2 2026 Earnings Call Transcript
Capricor Therapeutics (NASDAQ:CAPR) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a...
08-14 04:50
Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13
Capricor Therapeutics will release its Q2 2026 financial results on August 13, 2026, after market close, and host a conference call and webcast at 4:30 p.m. ET that day. The call can be accessed via toll-free numbers or a webcast link, with a replay available post-event on the company’s website. Capricor, a biotech firm developing cell and exosome-based therapies for rare diseases, is focused on advancing treatments like Deramiocel for Duchenne m...
08-10 12:30
Benzinga Bulls And Bears: Amazon, Microsoft, SpaceX
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks closed a volatile week mixed as investors navigated a hawkish Federal Reserve, surging Treasury yields and sharply divergent earnings from the biggest techno...
08-01 20:00
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Capricor downgraded at Oppenheimer after negative AdCom vote
Shares of Capricor Therapeutics (CAPR) lost more than 45% to reach a new 52-week low on Thursday as Oppenheimer downgraded the cell therapy developer after an FDA advisory committee failed to endorse ...
07-31 00:31
